Papulovesicular skin rash as early sign of COVID-19: a case report

Case Report

American Journal of BioMedicine
Volume 10, Issue 4, November 28 2022, Pages 172-177 |

Vaisakh Paul 1, Rija E Ghosh *

Received  June 10 2022   Revised  August 30 2022   Accepted  October 29 2022   Published  November 28 2022



COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has spread rapidly through human-to-human transmission worldwide since its first identification in Wuhan, China, in December of 2019. According to a 2021 study published in the British Journal of Dermatology, there is an association between skin rashes and a positive COVID-19 swab test result. A 32-year-old female patient without travel history, presented with a history of severe itching followed papulovesicular skin lesions of both thighs associated with low grade fever for three days then rapid involve legs, and chest since. Four days later develop flue like symptoms, headache, dry cough, and decreased appetite. Her skin manifestations disappeared completely 6 days after the onset of the disease, followed by the disappearance of cough. Rapid antigen test for COVID-19 was done which was positive. Later positive result from nasopharyngeal reverse transcriptase PCR swab.

Keywords: COVID-19; Dry cough; SARS-Cov-2; Papulovesicular skin lesions

Copyright © 2022 Vaisakh Paul, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to citeReferencesDownload citationStatistics
The citation data is computed by the following citation measuring services:

Hidden content
Hidden content
Hidden content
Hidden content
Hidden content
Hidden content
Hidden content
Hidden content

  1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323:1239-42.
  2. Manalo I, Smith M, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol 2020; 83:700.
  3. Xu R, Zhou Y, Cai L, et al. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br J Dermatol 2020; 183(6):1145-1147.
  4. Kuriyama Y, Shimizu A, Oka H, et al. Erythema nodosumlike eruption in coronavirus disease 2019: a case report and literature review of Asian countries. J Dermatol 2021; 48(10):1588-1592.
  5. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220:1-13.
  6. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis 2020; 71(15):889-90.
  7. McMahon DE, Gallman AE, Hruza GJ, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis 2021; 21(3):313-314
  8. Giraud-Kerleroux L, Mongereau M, Cassius C, et al. Detection of a second outbreak of chilblain-like lesions during COVID-19 pandemic through teledermatology. J Eur Acad Dermatol Venereol 2021; 35(9):e556-e558.
  9. Janah H, Zinebi A, Elbenaye J. Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2. J Eur Acad Dermatol Venereol 2020; 34:e373-5.
  10. Baeck M, Peeters C, Herman A. Chilblains and COVID-19: further evidence against a causal association. J Eur Acad Dermatol Venereol 2021; 35(1):e2-e3.
  11. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020; 83(1):280-285.
  12. Wollina U, Karadağ AS, Rowland Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID 19 patients: a review. Dermatol Ther 2020; e13549.
  13. Rongioletti F, Ferreli C, Sena P, Caputo V, Atzori L. Clinicopathologic correlations of COVID-19-related cutaneous manifestations with special emphasis on histopathologic patterns. Clin Dermatol 2021; 39(1):149-162.
  14. Guo YR, Cao QD, Hong ZS, Tan YY, et al. The origin, transmission and clinical therapies on Coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res 2020; 7:11.
  15. Fullerton J, Cabrera V. Special considerations for leukemic patients during the COVID-19 pandemic: meta-analysis study. NeuroQuantology 2022; 20(8):7509-7515.
  16. Visconti A, Bataille V, Rossi N, et al. Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection. Br J Dermatol 2021; 184(5):880-887.
  17. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20:533- 4.
  18. Recalcati S. Cutaneous manifestations in COVID- 19: a first perspective. J Eur Acad Dermatology Venereol 2020; 34.
  19. Carta MG, Preti A, Portoghese I, et al. Risk for depression, burnout and low quality of life among personnel of a university hospital in Italy is a consequence of the impact one economic crisis in the welfare system? Clin Pract Epidemiol Ment Health 2017; 13:156-67.
  20. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9:221- 36.
  21. Yousif N. Metastatic Cancer patients during COVID-19 pandemic: A longitudinal study of current evidence. Teikyo Medical Journal 2022; 45(04):6353-6359.
  22. Whittaker E, Bamford A, Kenny J, et al. Clinical and laboratory characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 8.
  23. Davis H, Assaf G, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38:101019.
  24. Conceição MS, Chetterje ED, Gupta M. Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis. Muthanna Medical Journal 2022; 6(1):57-67.
  25. Sharma A, Mesinkovska N, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol 2020; 83(2):563- 78.
  26. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20:533- 4.
  27. Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol 2020; 34(11):2505- 10.
  28. Andrees V, Klein TM, Augustin M, Otten M. Live interactive teledermatology compared to in-person care - a systematic review. J Eur Acad Dermatol Venereol 2020; 34:733-45.
  29. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269- 71.
  30. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev 2020; 7(7):CD013665.

1. Access through OpenAthens

2. PDF     XML

For any technique error please contact us.


      PDF           XML

How to cite this article
Paul V, Ghosh RE. Papulovesicular skin rash as early sign of COVID-19: a case report. American Journal of BioMedicine. 2022; 10(4):172-177

Article metric